Navigation Links
Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
Date:10/28/2010

nt to patients and their families."

This study was supported by funding from Shire Development Inc.  Dr Timothy Wilens was a speaker for, received grant support from, and is a consultant for Shire.  

*Suboptimal response was defined as treatment with a stable dose of stimulant for at least four weeks with improvement, yet persistence of mild to moderate ADHD symptoms in the opinion of the investigator (defined as an ADHD-RS-IV total score of at least 24, Clinical Global Impressions-Severity of illness scale score of at least three).  Patients with no response to stimulants prior to study enrollment were excluded from participating in this study.

About INTUNIV

INTUNIV™ (guanfacine) Extended-Release Tablets is a nonstimulant approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.  INTUNIV was approved by the US Food and Drug Administration (FDA) in September 2009 and comes in 4 doses—1 mg, 2 mg, 3 mg, and 4 mg.  INTUNIV should be taken once a day.

The active ingredient in INTUNIV is guanfacine.  INTUNIV is not a central nervous system (CNS) stimulant or a controlled substance.  It is not likely to cause dependence or be abused.

Additional information about INTUNIV and Full Prescribing Information are available at www.intunivpro.com.

Indication

INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.  Efficacy was established in two controlled clinical trials (8 and 9 weeks in duration).  The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient.

INTUNIV is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological,
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. 52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus
2. Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreichs Ataxia
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
5. Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
8. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
9. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
10. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 2015   Meditope Biosciences, Inc ., a biotechnology ... today announced presentation of data demonstrating the use of ... conjugates (ADCs). The data were presented in an abstract at ... in Philadelphia . ... to the many commercial applications that may be possible ...
(Date:4/18/2015)... PHILADELPHIA , April 18, 2015 ... (NASDAQ: CRIS ) will be presenting data ... the American Associate of Cancer Research Annual Meeting ... ).      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) ... its proprietary Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors ...
(Date:4/17/2015)... 2015 CIO Review ( http://www.cioreview.com ) ... Most Promising Pharma and Life Science Technology Solution Providers ... compliance software platform for life sciences companies. , ... panel of experts and members of CIO Review’s editorial ... Platform has been on our radar for some time ...
(Date:4/17/2015)... 17, 2015  US-Australian drug discovery company, Novogen, today ... Understanding with the Feinstein Institute for Medical Research ... to collaborate with the objective of developing ... collaboration brings together the drug discovery expertise of ... the Feinstein Institute in neurosciences and oncology. ...
Breaking Biology Technology:Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... Holdings, Inc. (Nasdaq: NHWK ), the leading ... United States, today announced that,Tim Mayleben, NightHawk,s President ... for personal reasons. Mayleben will remain with,NightHawk in ... and is,expected to resign from the board of ...
... Martek Biosciences,(Nasdaq: MATK ) announced today that ... eye and heart health, is now available in,two new ... Grapefruit Lychee and Marionberry Guava, join 10 existing flavors ... line is,available at natural food stores nationwide., "We ...
... Board of Directors, Ron ... Vice President Legal Affairs -, SEATTLE, Feb. 13 ... development of therapeutics for,autoimmune and inflammatory disorders, today announced ... of Dendreon Corporation,(Nasdaq: DNDN ), to the Company,s ...
Cached Biology Technology:NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures 2NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures 3Martek's life'sDHA(TM) Now Featured in Two New Flavors of Rachel's(R) Wickedly Delicious Yogurt from WhiteWave Foods 2Martek's life'sDHA(TM) Now Featured in Two New Flavors of Rachel's(R) Wickedly Delicious Yogurt from WhiteWave Foods 3VLST Corporation Announces Board and Executive Management Appointments 2VLST Corporation Announces Board and Executive Management Appointments 3
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... a room in the intensive care unit (ICU) ... may increase the odds of acquiring such bacteria, ... issue of Archives of Internal Medicine, one of ... significant illness and death in hospitals: methicillin-resistant Staphylococcus ...
... cold seeps--strange clams, mussels and sea snails that thrive in ... marine mollusk community as a whole, according to a new ... published by AAAS, the nonprofit science society. , On average, ... geological record is a full epoch earlier than that of ...
... Boston have demonstrated that it may be possible to ... the heart from scarring. Working with rats, they combined ... division with a naturally occurring growth factor that encourages ... heart-muscle cells to multiply and the heart to regain ...
Cached Biology News:Transmission of antibiotic-resistant bacteria linked to previous intensive care unit room occupants 2Ocean seep mollusks may share evolutionary history with other deep-sea creatures 2Ocean seep mollusks may share evolutionary history with other deep-sea creatures 3Rescuing injured hearts by enhancing regeneration 2Rescuing injured hearts by enhancing regeneration 3